👤 Shu Chen

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧬 Extraction
121
Articles
176
Name variants
Also published as: Lijuan Chen, PL Chen, R Chen, Jianxin Chen, Zhu Chen, Feng Chen, SRW Chen, K. Chen, D. Chen, KG Chen, L Chen, Fangman Chen, F. M. Chen, Qinjun Chen, Xiao-Xiao Chen, Xinli Chen, VB Chen, Jia-Wei Chen, Zhi-Lin Chen, H.T. Chen, R. Chen, Wen-Xiu Chen, K Chen, T. Chen, IH Chen, An‐Liang Chen, Wei-Qiang Chen, B Chen, Y. Chen, Dominique Chen, C Chen, Hao Chen, Q Chen, N. Chen, P Chen, Hongmin Chen, Zejing Chen, Y.H. Chen, Jintai Chen, Qiang Chen, DL Chen, Ming Chen, X.Y. Chen, Yu Chen, L. Chen, G. Chen, Jincan Chen, Zhen-Feng Chen, Hanjian Chen, J.L. Chen, Z Chen, Dian Yu Chen, F Chen, M Chen, Juan Chen, YT Chen, Shi-Long Chen, E. Chen, W Chen, CF Chen, Shili Chen, Jin-can Chen, SD Chen, J. Chen, Q. Chen, KH Chen, Ming-Cheng Chen, Y. A. Chen, Zhaoying Chen, Qingchang Chen, Yuncong Chen, H Chen, HZ Chen, LL Chen, Si-Dong Chen, Jianxiang Chen, Bing Chen, Lan-mei Chen, G.R. Chen, Fanglu Chen, Lihao Chen, H.C. Chen, Yanan Chen, M. Chen, YS Chen, Chao Chen, Luyao Chen, Mickey Chen, SX Chen, Lulu Chen, X. Chen, Zhiyi Chen, J.‐Y. Chen, Z.Y. Chen, WQ Chen, Xiao-Yan Chen, S. H. Chen, H. Chen, Xiaobing Chen, DC Chen, A. Chen, Yan-Hua Chen, S. Chen, Zena Chen, Mei-Ru Chen, Lanmei Chen, HD Chen, Kai Chen, Xiaoyuan Chen, Xin Chen, T Chen, Jie-Li Chen, PR Chen, Jia-Xi Chen, Z.F. Chen, S Chen, D Chen, L.P. Chen, Z. Chen, Y.L. Chen, Xi Chen, Liang Chen, Chen-Yu Chen, F. Chen, XY Chen, Shujiao Chen, X Chen, Yu-Hong Chen, DS Chen, Wenjing Chen, G Chen, P. Chen, Yulan Chen, Tianfeng Chen, Da-Qian Chen, S.M. Chen, Zhijian Chen, Jonathan Chen, Rui Chen, Hui Chen, Bing-Bing Chen, Shu-Sen Chen, Shengdong Chen, Y Chen, Shuhua Chen, B. Chen, Y. R. Chen, Sixun Chen, Tao Chen, HH Chen, P. N. Chen, Qiu-Yun Chen, M. T. Chen, Shan Chen, E. Y. Chen, ZP Chen, Junfa Chen, J. L. Chen, Jun Chen, JR Chen, Marian Y.‐H. Chen, PC Chen, HB Chen, Linxi Chen, J Chen, W. Chen, FX Chen, Yuan-Dao Chen, Qing Chen, Qingyu Chen, Guang-Chao Chen, LC Chen, C. Chen, Yuan‐Dao Chen, S.M.H. Chen
articles
M. Trent Kemp, Eric M. Lewandowski, Yu Chen · 2021 · Biochimica et biophysica acta · Elsevier · added 2026-04-20
Low-barrier hydrogen bonds (LBHBs) are a special type of short hydrogen bond (HB) that is characterized by the equal sharing of a hydrogen atom. The existence and catalytic role of LBHBs in proteins h Show more
Low-barrier hydrogen bonds (LBHBs) are a special type of short hydrogen bond (HB) that is characterized by the equal sharing of a hydrogen atom. The existence and catalytic role of LBHBs in proteins has been intensely contested. Advancements in X-ray and neutron diffraction methods has revealed delocalized hydrogen atoms involved in potential LBHBs in a number of proteins, while also demonstrating that short HBs are not necessarily LBHBs. More importantly, a series of experiments on ketosteroid isomerase (KSI) have suggested that LBHBs are significantly stronger than standard HBs in the protein microenvironment in terms of enthalpy, but not free energy. The discrepancy between the enthalpy and free energy of LBHBs offers clues to the challenges, and potential solutions, of the LBHB debate, where the unique strength of LBHBs plays a special role in the kinetic processes of enzyme function and structure, together with other molecular forces in a pre-organized environment. Show less
no PDF DOI: 10.1016/j.bbapap.2020.140557
amino-acid
Yanjing Yang, Lihua Guo, Jie Huang +7 more · 2021 · Dyes and Pigments · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.dyepig.2020.108867
Biometal
Lili Wang, Ruilin Guan, Lina Xie +6 more · 2021 · Angewandte Chemie · Wiley · added 2026-05-01
📄 PDF DOI: 10.1002/ange.202013987
Biometal
Hao Yuan, Zhong Han, Yuncong Chen +5 more · 2021 · Angewandte Chemie · Wiley · added 2026-05-01
📄 PDF DOI: 10.1002/ange.202014959
Biometal
Ruilin Guan, Lina Xie, Lili Wang +4 more · 2021 · Inorganic Chemistry Frontiers · Royal Society of Chemistry · added 2026-05-01
📄 PDF DOI: 10.1039/d0qi01430c
Biometal
Noor Shad Gul, Taj-Malook Khan, Yan-Cheng Liu +3 more · 2021 · CCS Chemistry · added 2026-05-01
no PDF DOI: 10.31635/ccschem.020.202000363
Biometal
Yamazaki, Takahiro, Takahiro Yamazaki, Buqué, Aitziber +9 more · 2020 · Humana, New York, NY · Springer · added 2026-04-20
In response to selected stressors, cancer cells can undergo a form of regulated cell death that—in immunocompetent syngeneic hosts—is capable of eliciting an adaptive immune response speci Show more
In response to selected stressors, cancer cells can undergo a form of regulated cell death that—in immunocompetent syngeneic hosts—is capable of eliciting an adaptive immune response specific for dead cell-associated antigens. Thus, such variant of... Show less
no PDF DOI: 10.1007/978-1-4939-9773-2_20
immunogenic
Qi Wang, Xi Chen, Yuhang Jiang +13 more · 2020 · Journal of molecular cell biology · Oxford University Press · added 2026-04-20
Histone methylation is a context-dependent modification that regulates gene expression, and the trimethylation of histone H3 lysine 27 (H3K27me3) usually induces gene silencing. Overcoming colorectal Show more
Histone methylation is a context-dependent modification that regulates gene expression, and the trimethylation of histone H3 lysine 27 (H3K27me3) usually induces gene silencing. Overcoming colorectal cancer (CRC) chemoresistance is currently a huge challenge, but the relationship between H3K27me3 modification and chemoresistance remains largely unclear. Here, we found that H3K27me3 levels positively correlated with the metastasis-free survival of CRC patients and a low H3K27me3 level predicted a poor outcome upon chemotherapeutic drug treatment. Oxaliplatin stimulation significantly induced the expression of H3K27 lysine demethylase 6A/6B (KDM6A/6B), thus decreasing the level of H3K27me3 in CRC cells. Elevation of H3K27me3 level through KDM6A/6B depletion or GSK-J4 (a KDM6A/6B inhibitor) treatment significantly enhanced oxaliplatin-induced apoptosis. Conversely, when inhibiting the expression of H3K27me3 by EPZ-6438, an inhibitor of the histone methyltransferase EZH2, the proportion of apoptotic cells remarkably decreased. In addition, the combination of GSK-J4 and oxaliplatin significantly inhibited tumor growth in an oxaliplatin-resistant patient-derived xenograft model. Importantly, we revealed that oxaliplatin treatment dramatically induced NOTCH2 expression, which was caused by downregulation of H3K27me3 level on the NOTCH2 transcription initiation site. Thus, the activated NOTCH signaling promoted the expression of stemness-related genes, which resulted in oxaliplatin resistance. Furthermore, oxaliplatin-induced NOTCH signaling could be interrupted by GSK-J4 treatment. Collectively, our findings suggest that elevating H3K27me3 level can improve drug sensitivity in CRC patients. Show less
no PDF DOI: 10.1093/jmcb/mjz032
S.J. Rayhan, K.M. Koeller, J.C. Wong +221 more · 2020 · Heliyon · Elsevier · added 2026-04-20
S.J. Rayhan, K.M. Koeller, J.C. Wong, R.A. Butcher, S.L. Schreiber, F.G. Kuruvilla, A.F. Shamji, S.M. Sternson, P.J. Hergenrother, D.B. Kitchen, H. Decornez, J.R. Furr, J. Bajorath, Z. Mousavian, A. Masoudi-Nejad, R.S. Olayan, H. Ashoor, V.B. Bajic, Y. Yamanishi, M. Araki, A. Gutteridge, W. Honda, M. Kanehisa, S. Khakabimamaghani, K. Kavousi, F. Rayhan, S. Ahmed, S. Shatabda, D.M. Farid, A. Dehzangi, M.S. Rahman, K. Tian, M. Shao, Y. Wang, J. Guan, S. Zhou, K.C. Chan, Z.-H. You, W. Wang, S. Yang, J. Li, X. Chen, M.-X. Liu, G.-Y. Yan, K. Bleakley, S. Alaimo, A. Pulvirenti, R. Giugno, A. Ferro, F. Cheng, C. Liu, J. Jiang, W. Lu, W. Li, G. Liu, W. Zhou, J. Huang, Y. Tang, Z. He, J. Zhang, X.-H. Shi, L.-L. Hu, X. Kong, Y.-D. Cai, K.-C. Chou, X. Xiao, J.-L. Min, P. Wang, J. Keum, H. Nam Self-blm, M. Hao, S.H. Bryant, M. Gönen, W. Ba-Alawi, O. Soufan, M. Essack, P. Kalnis, H. Chen, Z. Zhang, Y.-A. Huang, S. Daminelli, J.M. Thomas, C. Durán, C.V. Cannistraci, V.J. Haupt, M. Schroeder, Q. Yuan, J. Gao, D. Wu, S. Zhang, H. Mamitsuka, S. Zhu, L. Wang, S.-X. Xia, F. Liu, X. Yan, Y. Zhou, K.-J. Song, A. Ezzat, M. Wu, X.-L. Li, C.-K. Kwoh, C.C. Yan, X. Zhang, F. Dai, J. Yin, Y. Zhang, M. Wen, S. Niu, H. Sha, R. Yang, Y. Yun, H. Lu, Y. López, S.P. Lal, G. Taherzadeh, J. Michaelson, A. Sattar, T. Tsunoda, A. Sharma, A.W.-C. Liew, Y. Yang, Y. Freund, R.E. Schapire, I. Goodfellow, Y. Bengio, A. Courville, Y. Du, J. Wang, X. Wang, J. Chen, H. Chang, C. Szegedy, W. Liu, Y. Jia, P. Sermanet, S. Reed, D. Anguelov, D. Erhan, V. Vanhoucke, A. Rabinovich, S. Ioffe, J. Shlens, Z. Wojna, A.A. Alemi, M. Abadi, P. Barham, Z. Chen, A. Davis, J. Dean, M. Devin, S. Ghemawat, G. Irving, M. Isard, A. Mahbub, M. Jani, D.P. Kingma, J. Ba Adam, M. Lin, Q. Chen, S. Yan, D.S. Wishart, C. Knox, A.C. Guo, D. Cheng, S. Shrivastava, D. Tzur, B. Gautam, M. Hassanali, S. Goto, M. Hattori, M. Hirakawa, M. Itoh, T. Katayama, S. Kawashima, S. Okuda, T. Tokimatsu, I. Schomburg, A. Chang, C. Ebeling, M. Gremse, C. Heldt, G. Huhn, D. Schomburg, S. Günther, M. Kuhn, M. Dunkel, M. Campillos, C. Senger, E. Petsalaki, J. Ahmed, E.G. Urdiales, A. Gewiess, L.J. Jensen, D.-S. Cao, S. Liu, Q.-S. Xu, H.-M. Lu, J.-H. Huang, Q.-N. Hu, Y.-Z. Liang, J.H. Friedman, F. Pedregosa, G. Varoquaux, A. Gramfort, V. Michel, B. Thirion, O. Grisel, M. Blondel, P. Prettenhofer, R. Weiss, V. Dubourg, S.R. Safavian, D. Landgrebe, T. Joachims, C.M. Rahman, M. Kotera, P. Mutowo, A.P. Bento, N. Dedman, A. Gaulton, A. Hersey, J. Lomax, J.P. Overington Show less
The task of drug-target interaction prediction holds significant importance in pharmacology and therapeutic drug design. In this paper, we present FRnet-DTI, an auto-encoder based feature manipulation Show more
The task of drug-target interaction prediction holds significant importance in pharmacology and therapeutic drug design. In this paper, we present FRnet-DTI, an auto-encoder based feature manipulation and a convolutional neural network based classifier for drug target interaction prediction. Two convolutional neural networks are proposed: FRnet-Encode and FRnet-Predict. Here, one model is used for feature manipulation and the other one for classification. Using the first method FRnet-Encode, we generate 4096 features for each of the instances in each of the datasets and use the second method, FRnet-Predict, to identify interaction probability employing those features. We have tested our method on four gold standard datasets extensively used by other researchers. Experimental results shows that our method significantly improves over the state-of-the-art method on three out of four drug-target interaction gold standard datasets on both area under curve for Receiver Operating Characteristic (auROC) and area under Precision Recall curve (auPR) metric. We also introduce twenty new potential drug-target pairs for interaction based on high prediction scores. The source codes and implementation details of our methods are available from https://github.com/farshidrayhanuiu/FRnet-DTI/ and also readily available to use as an web application from http://farshidrayhan.pythonanywhere.com/FRnet-DTI/ . Show less
📄 PDF DOI: 10.1016/j.heliyon.2020.e03444
Au ML
K Robinson, JJ Griese, G Berggren +53 more · 2020 · Journal of Biological Inorganic Chemistry · Springer · added 2026-04-20
The association of proteins with metals, metalation, is challenging because the tightest binding metals are rarely the correct ones. Inside cells, correct metalation is enabled by controlled bioavaila Show more
The association of proteins with metals, metalation, is challenging because the tightest binding metals are rarely the correct ones. Inside cells, correct metalation is enabled by controlled bioavailability plus extra mechanisms for tricky combinations such as iron and manganese. Show less
📄 PDF DOI: 10.1007/s00775-020-01790-3
Fe
R Fan, D De Stefani, A Raffaello +96 more · 2020 · Nature · Nature · added 2026-04-20
Mitochondria take up Ca 2+ through the mitochondrial calcium uniporter complex to regulate energy production, cytosolic Ca 2+ signaling, and cell death 1 , 2 . In mammals, the uniporter complex (u Show more
Mitochondria take up Ca 2+ through the mitochondrial calcium uniporter complex to regulate energy production, cytosolic Ca 2+ signaling, and cell death 1 , 2 . In mammals, the uniporter complex (uniplex) contains four core components: the pore-forming MCU, gatekeeper MICU1 and MICU2, and an auxiliary EMRE subunit essential for Ca 2+ transport 3 – 8 . To prevent detrimental Ca 2+ overload, the activity of MCU must be tightly regulated by MICUs, which sense the changes in cytosolic Ca 2+ concentrations to switch MCU on and off 9 , 10 . Here, we report cryo-EM structures of human mitochondrial calcium uniporter holocomplex in inhibited and Ca 2+ -activated states. These structures define the architecture of this multi-component Ca 2+ uptake machinery and reveal the gating mechanism by which MICUs control uniporter activity. This work provides a framework for understanding regulated Ca 2+ uptake in mitochondria and lends clues to modulate uniporter activity for treating mitochondrial Ca 2+ overload-related diseases. Show less
no PDF DOI: 10.1038/s41586-020-2309-6
mitochondria
Xue-Wen Liu, Ning-Yi Liu, Yuan-Qing Deng +5 more · 2020 · Journal of Radiation Research and Applied Sciences · Taylor & Francis · added 2026-05-01
📄 PDF DOI: 10.1080/16878507.2020.1738033
Biometal
Xian-Lan Hong, Juan Xu, Rong-Hui Jiang +3 more · 2020 · Transition Metal Chemistry · Springer · added 2026-05-01
📄 PDF DOI: 10.1007/s11243-019-00365-9
Biometal
Xue‐Wen Liu, Yu‐Cai Tang, Ning‐Yi Liu +5 more · 2020 · Applied Organometallic Chemistry · Wiley · added 2026-05-01
📄 PDF DOI: 10.1002/aoc.5312
Biometal
Fangman Chen, Fan Zhang, Dan Shao +9 more · 2020 · Applied Materials Today · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.apmt.2020.100558
Biometal
Shi Kuang, Xinxing Liao, Xianrui Zhang +6 more · 2020 · Angewandte Chemie · Wiley · added 2026-05-01
📄 PDF DOI: 10.1002/ange.201915828
Biometal apoptosis
Shujiao Chen, Xicheng Liu, Xingxing Ge +7 more · 2020 · Inorganic Chemistry Frontiers · Royal Society of Chemistry · added 2026-05-01
📄 PDF DOI: 10.1039/c9qi01161g
Biometal
Zhishan Xu, Yuliang Yang, Xianglei Jia +5 more · 2020 · Inorganic Chemistry Frontiers · Royal Society of Chemistry · added 2026-05-01
📄 PDF DOI: 10.1039/c9qi01492f
Biometal
Zhi-Lin Chen, Bi-Qun Zou, Qi-Pin Qin +5 more · 2020 · Inorganic Chemistry Communications · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.inoche.2020.107854
Biometal
Dan Bai, Yi Tian, Kai Chen +6 more · 2020 · Dyes and Pigments · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.dyepig.2020.108635
Biometal
Yanjing Yang, Lihua Guo, Xingxing Ge +6 more · 2020 · Dyes and Pigments · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.dyepig.2020.108220
Biometal
Bing Chen, Ya Li, Ruifeng Song +2 more · 2019 · Molecular biology reports · Springer · added 2026-04-20
N6-methyladenosine (m6A) serves as a major RNA methylation modification and impacts the initiation and progression of various human cancers through diverse mechanisms. It has been reported that m6A RN Show more
N6-methyladenosine (m6A) serves as a major RNA methylation modification and impacts the initiation and progression of various human cancers through diverse mechanisms. It has been reported that m6A RNA methylation is involved in different physiological and pathological processes, including stem cell differentiation and motility, immune response, cellular stress, tissue renewal and viral infection. In this review, the m6A modification and its regulatory functions in a few major cancers is introduced. The detection approaches for the m6A sites identification are discussed. Additionally, the potential of the RNA m6A modification in clinical application is discussed. Show less
no PDF DOI: 10.1007/s11033-019-04655-4
review
Qinjun Chen, Lisha Liu, Yifei Lu +10 more · 2019 · Advanced Science · Wiley · added 2026-04-20
AbstractAnticancer therapies, which can induce cell death and elevate antitumor immune response in the meantime, are considered as effective treatments for many types of cancers. Immunogenic cell deat Show more
AbstractAnticancer therapies, which can induce cell death and elevate antitumor immune response in the meantime, are considered as effective treatments for many types of cancers. Immunogenic cell death (ICD) induced by chemodrugs is a promising and typical strategy to achieve cell cytotoxicity and immunological enhancement together. However, due to the low level of ICD induction and less tumor‐targeting accumulation, application of traditional ICD inducers is limited. Here, tumor‐targeting core–shell magnetic nanoparticles (ETP‐PtFeNP:α‐enolase targeting peptide modified Pt‐prodrug loaded Fe3O4 nanoparticles) are developed to reinforce ICD induction of loaded‐oxaliplatin (IV) prodrug. After tumor‐targeting accumulation and endocytosis, platinum (IV) complexes are activated by intracellular reductive elimination to yield and release the Pt (II) congener, oxaliplatin, leading to DNA lesions and reactive oxygen species (ROS) generation. Simultaneously, in‐progress‐released ferric ions elicit highly toxic ROS (·OH or ·OOH) burst and interfere with the intracytoplasmic redox balance (like endoplasmic reticulum stress), leading to ICD‐associated immunogenicity enhancement and specific antitumor immune responses to kill the tumor cells synergistically. Meanwhile, the transverse relaxation rate R 2 of ETP‐PtFeNP is remarkably increased by more than three times while triggered by reductant, suggesting ETP‐PtFeNP a high‐sensitivity T 2 contrast agent for magnetic resonance imaging. Show less
no PDF DOI: 10.1002/advs.201802134
Fe Pt ROS amino-acid anticancer drug-delivery imaging immunogenic
A Herbert, AG Herbert, JR Spitzner +187 more · 2019 · Communications Biology · Nature · added 2026-04-20
A Herbert, AG Herbert, JR Spitzner, K Lowenhaupt, A Rich, U Kim, Y Wang, T Sanford, Y Zeng, K Nishikura, JB Patterson, DC Thomis, SL Hans, CE Samuel, M Schade, T Schwartz, MA Rould, FM Pohl, TM Jovin, AH Wang, LJ Peck, JC Wang, PS Ho, MJ Ellison, GJ Quigley, K Kus, SC Ha, YG Kim, KK Kim, KM Vasquez, G Wang, M de Rosa, S Bae, D Kim, S Hohng, N Kolimi, Y Ajjugal, T Rathinavelan, JR Bothe, HM Al-Hashimi, D Placido, J Behlke, U Heinemann, S Zacarias, A Athanasiadis, VK Subramani, K Yun, JC Hartner, HJ Kang, WJ Chung, L D’Ascenzo, Q Vicens, P Auffinger, M Teplova, J Song, HY Gaw, A Teplov, DJ Patel, YM Abbas, A Pichlmair, MW Gorna, G Superti-Furga, B Nagar, BL Bass, O Solomon, A Strehblow, M Hallegger, MF Jantsch, CX George, Z Gan, Y Liu, M Sakurai, Y Zheng, C Lorenzo, PA Beal, K Honda, A Takaoka, T Taniguchi, P Vitali, AD Scadden, K Pestal, G Ramaswami, JB Li, H Cao, AP de Koning, W Gu, TA Castoe, MA Batzer, DD Pollock, PL Deininger, D Grover, M Mukerji, P Bhatnagar, K Kannan, SK Brahmachari, DD Kim, S Maas, EY Levanon, Y Kawahara, S Ahmad, NM Mannion, H Wu, K Stellos, PC Champ, S Maurice, JM Vargason, T Camp, JH Bahn, JV Ditlevson, RM Voorhees, RS Hegde, V Ahl, H Keller, S Schmidt, O Weichenrieder, M Halic, EA Bennett, S Lehnert, AL Price, E Eskin, PA Pevzner, CM Rubin, RH Kimura, CW Schmid, A Berger, E Ivanova, A Scherrer, E Alkalaeva, K Strub, IB Lomakin, TA Steitz, M Leroy, MH Nielsen, RK Flygaard, LB Jenner, JH Cate, S Feng, LL Chen, L Yang, SI Shin, R Liu, A Maruyama, J Mimura, N Harada, K Itoh, MS Ebert, PA Sharp, S Lukic, JC Nicolas, AJ Levine, AY Karpova, LV Ronco, PM Howley, J Galipon, R Ishii, Y Suzuki, M Tomita, K Ui-Tei, AJ Rutkowski, SD McKenna, SA Samarajiwa, H Ota, PV Maillard, V Tarallo, N Kerur, EA Costa, K Subramanian, J Nunnari, JS Weissman, B Szczesny, VR DeFilippis, D Alvarado, T Sali, S Rothenburg, K Fruh, Z Ma, B Damania, J Krol, C McCormick, DA Khaperskyy, B Van Treeck, C Mao, W Sun, NC Seeman, SK Ng, R Weissbach, GE Ronson, SA Kelly, TM Panhuis, AM Stoehr Show less
Left-handed Z-DNA/Z-RNA is bound with high affinity by the Zα domain protein family that includes ADAR (a double-stranded RNA editing enzyme), ZBP1 and viral orthologs regulating innate immunity. Loss Show more
Left-handed Z-DNA/Z-RNA is bound with high affinity by the Zα domain protein family that includes ADAR (a double-stranded RNA editing enzyme), ZBP1 and viral orthologs regulating innate immunity. Loss-of-function mutations in ADAR p150 allow persistent activation of the interferon system by Alu dsRNAs and are causal for Aicardi-Goutières Syndrome. Heterodimers of ADAR and DICER1 regulate the switch from RNA- to protein-centric immunity. Loss of DICER1 function produces age-related macular degeneration, a different type of Alu-mediated disease. The overlap of Z-forming sites with those for the signal recognition particle likely limits invasion of primate genomes by Alu retrotransposons. Show less
📄 PDF DOI: 10.1038/s42003-018-0237-x
amino-acid
Shenghua Shi, Huimin Lu, Tongguo Shi +96 more · 2019 · Cell Death & Disease · Nature · added 2026-04-20
Accumulating evidence suggests that aerobic glycolysis is important for colorectal cancer (CRC) development. However, the underlying mechanisms have yet to be elucidated. B7-H3, an immunoregulatory pr Show more
Accumulating evidence suggests that aerobic glycolysis is important for colorectal cancer (CRC) development. However, the underlying mechanisms have yet to be elucidated. B7-H3, an immunoregulatory protein, is broadly overexpressed by multiple tumor types and plays a vital role in tumor progression. In this study, we found that overexpression of B7-H3 effectively increased the rate of glucose consumption and lactate production, whereas knockdown of B7-H3 had the opposite effect. Furthermore, we showed that B7-H3 increased glucose consumption and lactate production by promoting hexokinase 2 (HK2) expression in CRC cells, and we also found that HK2 was a key mediator of B7-H3-induced CRC chemoresistance. Depletion of HK2 expression or treating cells with HK2 inhibitors could reverse the B7-H3-induced increase in aerobic glycolysis and B7-H3-endowed chemoresistance of cancer cells. Moreover, we verified a positive correlation between the expression of B7-H3 and HK2 in tumor tissues of CRC patients. Collectively, our findings suggest that B7-H3 may be a novel regulator of glucose metabolism and chemoresistance via controlling HK2 expression in CRC cells, a result that could help develop B7-H3 as a promising therapeutic target for CRC treatment. Show less
📄 PDF DOI: 10.1038/s41419-019-1549-6
amino-acid
Zhen-Hua Liang, Ya-Ning Wang, Zhi-Wei Xiong +2 more · 2019 · Transition Metal Chemistry · Springer · added 2026-05-01
📄 PDF DOI: 10.1007/s11243-019-00315-5
Biometal
Jianfu Zhao, Xiang Zhang, Hongxing Liu +3 more · 2019 · Journal of Organometallic Chemistry · Elsevier · added 2026-05-01
📄 PDF DOI: 10.1016/j.jorganchem.2019.07.020
Biometal
Xingxing Ge, Xicheng Liu, Zhenzhen Tian +7 more · 2019 · Applied Organometallic Chemistry · Wiley · added 2026-05-01
📄 PDF DOI: 10.1002/aoc.5171
Biometal
Jia Li, Hongmin Chen, Leli Zeng +5 more · 2019 · Inorganic Chemistry Frontiers · Royal Society of Chemistry · added 2026-05-01
📄 PDF DOI: 10.1039/C9QI00081J
Biometal
Min-Song Wu, Tao Fan, Shu-Sen Chen +2 more · 2018 · Organic Letters · ACS Publications · added 2026-04-20
A palladium(II)-catalyzed asymmetric 1,2-diamination of 1,3-dienes with readily available dialkylureas was established by using a chiral pyridine-oxazoline ligand. The diamination reaction exclusively Show more
A palladium(II)-catalyzed asymmetric 1,2-diamination of 1,3-dienes with readily available dialkylureas was established by using a chiral pyridine-oxazoline ligand. The diamination reaction exclusively occurs at the terminal C-C double bond of the 1,3-dienes to give 4-vinylimidazolidin-2-ones in high yields and with excellent levels of enantioselectivity (up to 99% yield, 97% ee). The reaction could feasibly be applied for gram-scale synthesis with a 1:1 ratio of the diene and the urea. Show less
no PDF DOI: 10.1021/acs.orglett.8b00870
Pd